Local prevalence and management of Janus kinase inhibitor-induced acne among adolescents with inflammatory bowel disease.

PubMed 2026 Open access

Read full text
Authors: Anna Isabella Shanker Barclay, Caroline H T Hall, Carla Torres-Zegarra, Sofia Guelfand Warnken, Shannon White, Brad D. Constant
DOI: 10.1093/crocol/otag007
Cited by: 0

Abstract

Background: Janus kinase inhibitors (JAKi), including tofacitinib and upadacitinib, are small-molecule medications effective in treating inflammatory bowel disease (IBD) and other immune-mediated disorders. In adult IBD clinical trials for JAKi, acne is a commonly reported adverse event. There are currently no data on the prevalence of acne in pediatric patients with IBD treated with JAKi. In this manuscript, we sought to estimate the local prevalence, characteristics, and treatment patterns of JAKi-induced acne among pediatric patients with IBD. Methods: We completed a retrospective chart review of children (age

Fields of Study & Subjects

Acne and Rosacea Treatments and Effects Inflammatory Bowel Disease Dermatology and Skin Diseases

Publication details

Journal / source
PubMed
Volume
8
Issue
1
Pages
otag007–otag007
Publication date
1 January 2026
Language
EN